PHASE 1b STUDY OF HS-20122 COMBINED THERAPY IN NSCLC

This is a multi-center, open-label, phase I study to evaluate the safety, efficacy, pharmacokinetics (PK), and immunogenicity of HS-20122 combined therapy in subjects with locally advanced or metastatic non-small cell lung cancer (NSCLC).

Trial Details

NCT ID
NCT07645222
Phase
PHASE1
Sponsor
Hansoh BioMedical R&D Company
Status
RECRUITING
Cancer Type
Non-Small Cell (NSCLC) Lung Cancer
Interventions
  • HS-20122+Aumolertinib
  • HS-20122+Adbrelimab
  • HS-20122+Adbrelimab+Platinum-based Chemo
Locations (sample)
  • Guangzhou, Guangdong, China|23.11667,113.25

Key Eligibility Criteria

  • Locally advanced or metastastic NSCLC;
  • Received at least 1 line SoC,or treatment naïve;
  • With at least 1 target lesion according to RECIST 1.1.
  • Appropriate organ function

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Small Cell (NSCLC) Lung Cancer Trials on Trialify →